|
gptkbp:instanceOf
|
gptkb:brand
antipsychotic medication
|
|
gptkbp:activeIngredient
|
paliperidone palmitate
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:Risperdal_Consta
gptkb:Invega_Hafyera
gptkb:Invega_Trinza
|
|
gptkbp:ATCCode
|
N05AX13
|
|
gptkbp:contraindication
|
hypersensitivity to paliperidone
|
|
gptkbp:dosageFrequency
|
monthly
|
|
gptkbp:firstDoseRegimen
|
234 mg on day 1, 156 mg on day 8
|
|
gptkbp:form
|
long-acting injectable
|
|
gptkbp:genericName
|
paliperidone palmitate
|
|
gptkbp:halfLife
|
25 to 49 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Invega Sustenna
|
|
gptkbp:indication
|
gptkb:schizoaffective_disorder
schizophrenia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:maintenanceDose
|
39 mg to 234 mg monthly
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:risperidone
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:prescriptionRequired
|
https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
injection site reaction
weight gain
drowsiness
akathisia
prolactin increase
|
|
gptkbp:storage
|
20°C to 25°C (68°F to 77°F)
|
|
gptkbp:bfsParent
|
gptkb:Invega
|
|
gptkbp:bfsLayer
|
6
|